ABBV vs. BMRN: AbbVie vs. BioMarin Pharmaceutical Stock Comparison
How do AbbVie (ABBV) and BioMarin Pharmaceutical (BMRN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
AbbVie (ABBV) and BioMarin Pharmaceutical (BMRN) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | ABBV | BMRN |
|---|---|---|
| Name | AbbVie Inc. | BioMarin Pharmaceutical Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 514.92 billion USD | 10.85 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | January 2, 2013 | July 26, 1999 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ABBV | BMRN |
|---|---|---|
| Total Return (1Y) | 37.33% | 8.82% |
| Total Return (3Y, Annualized) | 32.74% | -12.54% |
| Total Return (5Y, Annualized) | 24.73% | -7.51% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ABBV | BMRN |
|---|---|---|
| Volatility (1Y, Annualized) | 25.65% | 35.50% |
| Beta (5Y) | 0.21 | 0.24 |
| Max Drawdown (5Y) | -21.92% | -57.64% |
| Avg. Volume (3M) | 4.76M | 2.28M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ABBV | BMRN |
|---|---|---|
| Sharpe Ratio (1Y) | 1.29 | 0.13 |
| Sortino Ratio (1Y) | 2.02 | 0.23 |
Profitability
ROE (TTM)
AbbVie (ABBV) has no ROE value reported for this period; BioMarin Pharmaceutical (BMRN) reports a negative figure of -0.31%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- ABBV
- --
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.31%
- Max
- 109.18%
- Q3
- 6.23%
- BMRN
- -0.31%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
BioMarin Pharmaceutical (BMRN) reports a negative net margin of -0.52%, usually indicating a net loss over the period. Meanwhile AbbVie (ABBV) reports 15.67%, ranking against industry peers normally.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
15.67%
- Max
- 18.05%
- ABBV
- 15.67%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.52%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- BMRN
- -0.52%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both AbbVie (ABBV) at 39.59% and BioMarin Pharmaceutical (BMRN) at 26.58% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
39.59%
- Max
- 83.12%
- ABBV
- 39.59%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.58%
- Max
- 83.12%
- BMRN
- 26.58%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ABBV | BMRN |
|---|---|---|
| ROE (TTM) | -- | -0.31% |
| ROA (TTM) | 10.74% | 3.89% |
| Net Margin (TTM) | 15.67% | -0.52% |
| Operating Margin (TTM) | 39.59% | 26.58% |
| Gross Margin (TTM) | 73.72% | 53.21% |
Growth
Revenue Growth
Both AbbVie (ABBV) at 8.57% and BioMarin Pharmaceutical (BMRN) at 12.87% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Both AbbVie (ABBV) at -0.84% and BioMarin Pharmaceutical (BMRN) at -18.55% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | ABBV | BMRN |
|---|---|---|
| Revenue Growth (YoY) | 8.57% | 12.87% |
| Revenue Growth (3Y CAGR) | 1.75% | 15.40% |
| EPS Growth (YoY) | -0.84% | -18.55% |
| EPS Growth (3Y CAGR) | -29.03% | 33.89% |
Financial Strength
Current Ratio (MRQ)
Both AbbVie (ABBV) at 0.87 and BioMarin Pharmaceutical (BMRN) at 2.44 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.87
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- ABBV
- 0.87
- Min
- 0.10
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.44
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- BMRN
- 2.44
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: BioMarin Pharmaceutical (BMRN) carries debt-to-equity ratio of 0.67 against its industry range, while AbbVie (ABBV) reports no figure this period.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- ABBV
- --
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.67
- Max
- 1.42
- BMRN
- 0.67
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ABBV | BMRN |
|---|---|---|
| Current Ratio (MRQ) | 0.87 | 2.44 |
| Debt / Equity (MRQ) | -- | 0.67 |
| Net Debt / EBITDA | 2.21 | 4.04 |
Dividends
Dividend Yield (TTM)
BioMarin Pharmaceutical (BMRN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AbbVie (ABBV) reports a yield of 2.40%, ranking against industry peers normally.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.40%
- ABBV
- 2.40%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
AbbVie (ABBV) reports payout ratio above 100% at 117.35%, meaning dividends exceeded current-period earnings; BioMarin Pharmaceutical (BMRN) pays no dividend (payout 0.00%).
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
117.35%
- ABBV
- 117.35%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ABBV | BMRN |
|---|---|---|
| Dividend Yield (TTM) | 2.40% | 0.00% |
| Dividend Payout Ratio (TTM) | 117.35% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: AbbVie (ABBV) trades at 50.05 times trailing earnings, ranked against its peers, while BioMarin Pharmaceutical (BMRN) has no P/E ratio this period.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
50.05
- Max
- 85.34
- ABBV
- 50.05
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- BMRN
- --
P/S Ratio (TTM)
BioMarin Pharmaceutical (BMRN) at 2.97 sits in the cheaper P/S ratio quartile while AbbVie (ABBV) at 7.80 prices around its industry’s middle — BMRN costs less per dollar of sales, though read it alongside growth and margins.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.80
- Max
- 58.18
- Q3
- 25.77
- ABBV
- 7.80
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.97
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- BMRN
- 2.97
- Min
- 0.01
P/B Ratio (MRQ)
AbbVie (ABBV) reports a negative P/B ratio of -112.34, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile BioMarin Pharmaceutical (BMRN) reports 1.73, ranking against industry peers normally.
ABBV
Pharmaceuticals, Biotechnology & Life Sciences industry group
-112.34
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
- ABBV
- -112.34
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.73
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- BMRN
- 1.73
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ABBV | BMRN |
|---|---|---|
| P/E Ratio (TTM) | 50.05 | -- |
| P/S Ratio (TTM) | 7.80 | 2.97 |
| P/B Ratio (MRQ) | -112.34 | 1.73 |
| Free Cash Flow Yield (TTM) | 3.44% | -0.15% |